CLEVELAND, Dec. 19, 2019 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced today that Sparrow Health System in
Lansing, Michigan has begun
patient treatments with MRIdian® Linac, a cutting-edge radiation
therapy system that combines the latest innovations in precision
radiation delivery and ground-breaking MRI-guidance. The MRIdian
device is located in the hospital's new Herbert-Herman Cancer
Center, designed to deliver convenient and comprehensive patient
care.
In the first weeks of MRIdian patient treatments, the team at
Sparrow Health System has been able to treat challenging cases such
as pancreatic cancer and centrally located lung lesions. MRIdian's
precision is allowing the team to deliver stereotactic body
radiation therapy (SBRT)—high doses of radiation delivered to
targeted areas. The goal of SBRT is to irradiate the tumor,
mitigate side effects and impact to healthy surrounding tissue, and
provide greater convenience to patients as fewer treatment sessions
are required.
"This is breakthrough technology. We're able to capture
high-resolution images while delivering radiation therapy
simultaneously. This increases treatment options available to our
cancer patients," said Luciano
DiCarlo, M.D., Radiation Oncologist, Sparrow Herbert-Herman
Cancer Center. "With MRIdian we can now see what's happening inside
the body while we deliver treatment to make sure we're targeting
the cancer and avoiding nearby healthy tissue and organs. This
takes radiation therapy to an entirely new level and allows us to
deliver higher doses. We're bringing a more precise and
personalized approach to radiation therapy."
Unlike conventional radiotherapy, the MRIdian system provides
diagnostic-quality MR visualization of soft-tissue targets and
surrounding organs. With MRIdian, clinicians can make daily
on-table treatment plan modifications to dynamically adjust
radiation beam delivery for subtle anatomical changes that may
occur, both during treatment delivery and throughout the course of
treatment. Combined, these capabilities provide the potential for
improved targeting precision and thus the delivery of higher
radiation doses.
"Advancing MRIdian's innovation beyond academic institutions is
an important step in patient care as the vast majority of U.S.
cancer patients receive treatment in the community hospital
setting," said Jim Alecxih, ViewRay's Chief Commercial
Officer. "Sparrow Health System utilized on-table adaptive therapy
in complex cases on day one of treatment, leveraging the breadth of
MRIdian's specialized capabilities. This is a meaningful step
forward in cancer care for patients around the
world."
ViewRay's MRIdian system has already been installed at 31
leading hospitals around the world where it is being used to treat
a wide variety of solid tumors and is the focus of numerous ongoing
clinical trials. MRIdian has been the subject of hundreds of
peer-reviewed publications, scientific meeting abstracts and
presentations. More than 6,500 patients have been treated with
MRIdian. For a list of treatment centers, please visit:
https://viewray.com/mridian-locator.
About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets
the MRIdian® radiation therapy system. MRIdian is built upon a
proprietary high-definition MR imaging system designed from the
ground up to address the unique challenges and clinical workflow
for advanced radiation oncology. Unlike MR systems used in
diagnostic radiology, MRIdian's high-definition MR was purpose
built to address specific challenges, including beam distortion,
skin toxicity, and other concerns that potentially may arise when
high magnetic fields interact with radiation beams. ViewRay and
MRIdian are registered trademarks of ViewRay, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Private Securities Litigation
Reform Act. Statements in this press release that are not purely
historical are forward-looking statements. Such forward-looking
statements include, among other things, the rate of new orders,
upgrades and installations, ViewRay's financial guidance for the
full year 2019 and ViewRay's conference call to discuss its second
quarter results. Actual results could differ from those projected
in any forward-looking statements due to numerous factors. Such
factors include, among others, the ability to commercialize MRIdian
Linac System, demand for ViewRay's products, the ability to convert
backlog into revenue, and the timing of delivery of ViewRay's
products, the timing, results and other uncertainties associated
with clinical trials, the ability to raise the additional funding
needed to continue to pursue ViewRay's business and product
development plans, the inherent uncertainties associated with
developing new products or technologies, competition in the
industry in which ViewRay operates and overall market conditions.
For a further description of the risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to ViewRay's
business in general, see ViewRay's current and future reports filed
with the Securities and Exchange Commission, including its Annual
Report on Form 10-K for the fiscal year ended December 31, 2018 and its Quarterly Reports on
Form 10-Q for the fiscal quarters ended March 31, 2019, June 30,
2019, and September 30, 2019
as updated periodically by the company's other filings with the
SEC. These forward-looking statements are made as of the date of
this press release, and ViewRay assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/michigan-community-hospital-begins-patient-treatments-with-viewrays-mridian-linac-300977391.html
SOURCE ViewRay, Inc.